Absorption, Metabolism, and Excretion of Taselisib (GDC-0032) , a Potent fl-Sparing PI3K Inhibitor in Rats, Dogs, and Humans

Shuguang Ma,Sungjoon Cho,Srikumar Sahasranaman,Weiping Zhao,Jodie Pang,Xiao Ding,Brian Dean,Bin Wang,Jerry Y. Hsu,Joseph Ware,Laurent Salphati
DOI: https://doi.org/10.1124/dmd.122.001096
2023-01-01
Drug Metabolism and Disposition
Abstract:Taselisib (also known as GDC-0032) is a potent and selective phos-phoinositide 3-kinase (PI3K) inhibitor that displays greater selectivity for mutant PI3Ka than wild-type PI3Ka. To better understand the absorption, distribution, metabolism, and excretion properties of ta-selisib, mass balance studies were conducted following single oral doses of [14C]taselisib in rats, dogs, and humans. Absolute bioavail-ability (ABA) of taselisib in humans was determined by oral adminis-tration of taselisib at the therapeutic dose followed by intravenous dosing of [14C]taselisib as a microtracer. The ABA in humans was 57.4%. Absorption of taselisib was rapid in rats and dogs and moder-ately slow in humans. The recovery of radioactivity in excreta was high (>96%) in the three species where feces was the major route of excretion. Taselisib was the major circulating component in the three species with no metabolite accounting for >10% of the total drug -derived material. The fraction absorbed of taselisib was 35.9% in rats and 71.4% in dogs. In rats, absorbed drug underwent moderate to extensive metabolism and biliary excretion of taselisib was minor. In dog, biliary excretion and metabolism were major clearance pathways. In humans, 84.2% of the dose was recovered as the parent drug in ex-creta indicating that metabolism played a minor role in the drug's clear-ance. Major metabolism pathways were oxidation and amide hydrolysis in the three species while methylation was another prominent metabo-lism pathway in dogs. The site of methylation was identified on the tria-zole moiety. In vitro experiments characterized that the N-methylation was dog-specific and likely mediated by a thiol methyltransferase.SIGNIFICANCE STATEMENT This study provides a comprehensive description of the absorption, distribution, and metabolism and pharmacokinetic properties of taseli-sib in preclinical species and humans. This study demonstrated the im-portance of oral bioavailability results for understanding taselisib's clearance pathways. The study also describes the identification and characterization of a unique dog-specific N-methylation metabolite of taselisib and the enzyme mediating N-methylation in vitro.
What problem does this paper attempt to address?